Navigation Links
Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
Date:4/8/2008

year, we anticipate launching certain new and unique, high margin value-added rice bran oil in major South American cities and the United States.

"The expansion we have begun not only increases future product volumes, but will also add proprietary technologies to broaden our portfolio to introduce innovative value-added rice bran oil and deoiled bran products that have never been available before," said Leo Gingras, Chief Operating Officer of NutraCea.

"The plant is ideally located to service South American demand and is closely located to a major port facility providing ready access to export markets. The world demand for healthy edible oils and specialty products, especially those derived from rice bran oil is at unprecedented levels and we intend to fully optimize Irgovel to help meet this need," Gingras added.

About NutraCea

NutraCea is a leader in stabilized rice bran nutrient research and dietary supplement development. The company manufactures as well as distributes products and food ingredients made from Rice Bran through its proprietary technology and processes. The Company has developed intellectual properties and created a range of proprietary product formulations, delivery systems and whole-food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a wasted by-product of standard rice processing. In addition to its whole-foods products, NutraCea develops families of health-promoting "nutraceuticals," including natural arthritic relief and cholesterol-lowering products. More information can be found in the company's filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding our utilization and expansion of capacity at our facility in
'/>"/>

SOURCE NutraCea
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Consumers Offer to Pay More to Satisfy Health Demands
2. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
3. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
4. DuPont Focused on Meeting Global Demands for Greater Safety & Protection
5. BioProcessors Launches SimCell(TM) Services to Meet Increased Customer Demand
6. Dynamic Energy Systems Goes Online and On-Demand
7. ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products
8. The Physical Therapy Profession Remains in High Demand
9. Caregivers Demand County Honor Their Contract
10. US-Based Bollywood On-Demand Service to Sponsor Faces of India YouthAIDS Gala on November 2nd
11. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8